The FDA has approved mifepristone (Korlym, Corcept Therapeutics) for controlling hyperglycemia in adults with endogenous Cushing’s syndrome. The drug was approved for use in patients who also have type 2 diabetes or glucose intolerance and in whom surgery is either contraindicated or has proven unsuccessful.
Source: FDA.
